Abstract:Objective While studies have documented how metabolic dysfunction-associated steatotic liver disease (MASLD) can contribute to cardiovascular disease (CVD), whether MASLD is associated with myocardial infarction (MI) remains debateable. Herein, we systematically reviewed published articles and performed a meta-analysis to determine the relationship between MASLD and MI risk. Methods PubMed, MEDLINE, Embase, Web of Science, CNKI, CBM, VIP, and WanFang databases were searched, and the DerSimonian Laird method was used to obtain hazard ratios (HRs) for binary variables to assess the correlation between MASLD and MI risk. Subgroup analyses for the study region, MASLD diagnosis, quality score, study design, and follow-up time were conducted simultaneously for the selected studies retrieved from the time of database establishment to March 2022. All study procedures were independently conducted by two investigators. Results The final analysis included seven articles, including eight prospective and two retrospective cohort studies. The MI risk was higher among MASLD patients than among non-MASLD patients (HR = 1.26; 95% CI: 1.08-1.47, p = 0.003). The results of the subgroup analysis of the study region revealed an association of MASLD with MI risk among Americans and Asians, but not in Europeans. Subgroup analyses of MASLD diagnosis showed that ultrasonography and other (fatty liver index[FLI] and computed tomography [CT)]) diagnostic methods, but not international classification of disease (ICD), increased the risk of MI. Subgroup analysis of the study design demonstrated a stronger relationship between MASLD and MI in retrospective studies but not in prospective studies. Subgroup analysis based on the follow-up duration revealed the association of MASLD with MI risk in cases with < 3 years of follow-up but not with ≥3 years of follow-up. Conclusion MASLD increases the risk of MI, independent of traditional risk factors.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: whether metabolic - dysfunction - associated steatotic liver disease (MASLD) is related to an increased risk of myocardial infarction (MI). Although previous studies have shown that MASLD can lead to cardiovascular disease (CVD), the specific association between MASLD and myocardial infarction remains controversial. Therefore, the authors determined the relationship between MASLD and the risk of myocardial infarction through a systematic review and meta - analysis. ### Research Background Metabolic - dysfunction - associated steatotic liver disease (MASLD) is a common chronic liver metabolic disease, affecting more than 25% of adults worldwide, especially more common in patients with type 2 diabetes. MASLD will not only gradually develop into non - alcoholic steatohepatitis (NASH), cirrhosis and liver failure, but also is closely related to the occurrence of cardiovascular disease (CVD). As one of the common causes of death, the incidence of myocardial infarction is gradually increasing, so it is of great significance to explore new predictors. ### Research Objectives This paper aims to evaluate the relationship between MASLD and the risk of myocardial infarction through a systematic review and meta - analysis, and to explore the influence of factors such as different regions, diagnostic methods, research designs and follow - up times on this relationship. ### Main Findings 1. **Overall Results**: - The MI risk in MASLD patients is significantly higher than that in non - MASLD patients (HR = 1.26; 95% CI: 1.08 - 1.47, p = 0.003). 2. **Sub - group Analyses**: - **Region**: MASLD is significantly associated with MI risk in American and Asian populations (HRs are 1.49 respectively), but there is no significant association in European populations. - **Diagnostic Methods**: MASLD diagnosed by ultrasound and other diagnostic methods (such as fatty liver index [FLI] and CT) is associated with an increased risk of MI, while there is no significant association in the diagnosis by International Classification of Diseases (ICD). - **Research Design**: Retrospective cohort studies show a stronger correlation between MASLD and MI, while there is no significant association in prospective cohort studies. - **Follow - up Time**: In studies with a follow - up time of less than 3 years, MASLD is significantly associated with MI risk; while in studies with a follow - up time of ≥3 years, there is no significant association. ### Conclusions MASLD increases the risk of myocardial infarction independently of traditional risk factors. Therefore, it is crucial to strictly monitor MASLD patients to prevent myocardial infarction. Future research should further explore whether active intervention in MASLD can reduce the incidence of myocardial infarction. Through these findings, this study provides an important scientific basis for understanding the relationship between MASLD and myocardial infarction, and emphasizes the importance of early identification and intervention in MASLD.

The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease

Long‐term risk of cardiovascular disease associated with MASLD and different cardiometabolic risk factors in IBD patients: A prospective cohort study

Metabolic Dysfunction‐Associated Steatotic Liver Disease Increases the Risk of Severe Infection: A Population‐Based Cohort Study

Association between MASLD and increased risk of serious bacterial infections requiring hospital admission: A meta-analysis

Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease

Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review

Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality

Electrocardiographic Abnormalities in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis

Metabolic syndrome traits differentially and cumulatively influence micro- and macrovascular disease risk in patients with MASLD

Association between metabolic dysfunction-associated steatotic liver disease and risk of urolithiasis: an updated systematic review and meta-analysis

Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies

MAFLD predicts cardiovascular disease risk better than MASLD

Metabolic-associated steatotic liver disease and risk of Alzheimer's disease: a real-world retrospective cohort study

High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease

Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease

Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study

Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study

Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups

Association between the composite dietary antioxidant index and metabolic dysfunction-associated steatotic liver disease in adults: a cross-sectional study from NHANES 2017–2020